Publications by authors named "Jefanie Teo"
Article Synopsis
- SARS-CoV-2 variants and reduced vaccine immunity have led to increased cases of breakthrough infections, highlighting the need to understand vaccine protection mechanisms.
- Researchers analyzed mRNA vaccinated individuals in Singapore during the Omicron surge to compare immune responses.
- Findings suggest those who stayed uninfected developed a stronger variant-specific IgA response after booster shots, indicating IgA may play an important role in protecting against Omicron.
Waning antibody levels against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the emergence of variants of concern highlight the need for booster vaccinations. This is particularly important for the elderly population, who are at a higher risk of developing severe coronavirus disease 2019 (COVID-19) disease. While studies have shown increased antibody responses following booster vaccination, understanding the changes in T and B cell compartments induced by a third vaccine dose remains limited.
View Article and Find Full Text PDFBackground: Over 2021, COVID-19 vaccination programs worldwide focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore, two mRNA vaccines (BNT162b2 and mRNA-1273) and the inactivated vaccine CoronaVac are currently authorized under the National Vaccination Programme for use as the primary vaccination series. More than 90% of the Singapore population has received at least one dose of a COVID-19 vaccine as of December 2021.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the efficacy of different COVID-19 vaccine booster combinations to enhance immune response against the Omicron variant, addressing concerns about decreasing antibody levels after vaccination and the emergence of variants.
- A total of 100 individuals who initially received the BNT162b2 vaccine were randomly assigned to receive either a homologous booster (BBB) or a heterologous mRNA-1273 booster (BBM), with antibody levels measured 28 days after the booster.
- Findings revealed that the heterologous booster (BBM) led to significantly higher levels of neutralizing antibodies compared to the homologous booster (BBB), particularly in older adults, highlighting the potential benefits of mixed vaccine approaches for improved protection against emerging variants.